Does the media refer more to NAMS or GMAB?

In the previous week, NewAmsterdam Pharma had 5 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for NewAmsterdam Pharma and 3 mentions for Genmab A/S. NewAmsterdam Pharma's average media sentiment score of 0.87 beat Genmab A/S's score of 0.72 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or NAMS?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 8 mentions for NewAmsterdam Pharma. Ascendis Pharma A/S's average media sentiment score of 1.31 beat NewAmsterdam Pharma's score of 0.87 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NAMS or BBIO?

In the previous week, BridgeBio Pharma had 6 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 14 mentions for BridgeBio Pharma and 8 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.87 beat BridgeBio Pharma's score of 0.64 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SMMT or NAMS?

In the previous week, Summit Therapeutics and Summit Therapeutics both had 8 articles in the media. NewAmsterdam Pharma's average media sentiment score of 0.87 beat Summit Therapeutics' score of 0.39 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral NewAmsterdam Pharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NAMS or AXSM?

In the previous week, Axsome Therapeutics had 5 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 13 mentions for Axsome Therapeutics and 8 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.87 beat Axsome Therapeutics' score of 0.51 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NewAmsterdam Pharma (NAMS) Competitors

$32.19 +0.48 (+1.51%)

As of 11:15 AM Eastern

Compare

NAMS vs. GMAB, ASND, BBIO, SMMT, and AXSM

Should you buy NewAmsterdam Pharma stock or one of its competitors? MarketBeat compares NewAmsterdam Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NewAmsterdam Pharma include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Summit Therapeutics (SMMT), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does NewAmsterdam Pharma compare to Genmab A/S?

NewAmsterdam Pharma (NASDAQ:NAMS) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

NewAmsterdam Pharma currently has a consensus price target of $48.00, suggesting a potential upside of 49.11%. Genmab A/S has a consensus price target of $37.93, suggesting a potential upside of 60.17%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, NewAmsterdam Pharma had 5 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for NewAmsterdam Pharma and 3 mentions for Genmab A/S. NewAmsterdam Pharma's average media sentiment score of 0.87 beat Genmab A/S's score of 0.72 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Genmab A/S has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.57M	166.77	-$203.82M	-$1.79	N/A
Genmab A/S	$3.72B	3.97	$963M	$1.32	17.94

NewAmsterdam Pharma has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Genmab A/S has a net margin of 21.05% compared to NewAmsterdam Pharma's net margin of -943.23%. Genmab A/S's return on equity of 15.34% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Genmab A/S	21.05%	15.34%	8.94%

Summary

Genmab A/S beats NewAmsterdam Pharma on 9 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 8 mentions for NewAmsterdam Pharma. Ascendis Pharma A/S's average media sentiment score of 1.31 beat NewAmsterdam Pharma's score of 0.87 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market.

Ascendis Pharma A/S presently has a consensus target price of $295.39, indicating a potential upside of 36.55%. NewAmsterdam Pharma has a consensus target price of $48.00, indicating a potential upside of 49.11%. Given NewAmsterdam Pharma's higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Ascendis Pharma A/S has a net margin of 57.87% compared to NewAmsterdam Pharma's net margin of -943.23%. Ascendis Pharma A/S's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

NewAmsterdam Pharma has lower revenue, but higher earnings than Ascendis Pharma A/S. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	16.57	-$258M	$8.67	24.95
NewAmsterdam Pharma	$22.57M	166.77	-$203.82M	-$1.79	N/A

Summary

Ascendis Pharma A/S beats NewAmsterdam Pharma on 13 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to BridgeBio Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NewAmsterdam Pharma presently has a consensus price target of $48.00, indicating a potential upside of 49.11%. BridgeBio Pharma has a consensus price target of $89.59, indicating a potential upside of 38.30%. Given NewAmsterdam Pharma's higher possible upside, equities analysts plainly believe NewAmsterdam Pharma is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

BridgeBio Pharma has a net margin of -124.42% compared to NewAmsterdam Pharma's net margin of -943.23%. BridgeBio Pharma's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
BridgeBio Pharma	-124.42%	N/A	-65.81%

NewAmsterdam Pharma has higher earnings, but lower revenue than BridgeBio Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.57M	166.77	-$203.82M	-$1.79	N/A
BridgeBio Pharma	$502.08M	25.27	-$724.93M	-$3.74	N/A

NewAmsterdam Pharma has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 6 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 14 mentions for BridgeBio Pharma and 8 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.87 beat BridgeBio Pharma's score of 0.64 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BridgeBio Pharma beats NewAmsterdam Pharma on 10 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

NewAmsterdam Pharma has higher revenue and earnings than Summit Therapeutics. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
NewAmsterdam Pharma	$22.57M	166.77	-$203.82M	-$1.79	N/A

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summit Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Summit Therapeutics currently has a consensus price target of $26.05, indicating a potential upside of 74.39%. NewAmsterdam Pharma has a consensus price target of $48.00, indicating a potential upside of 49.11%. Given Summit Therapeutics' higher probable upside, equities research analysts clearly believe Summit Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summit Therapeutics has a beta of -1.32, meaning that its stock price is 232% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

In the previous week, Summit Therapeutics and Summit Therapeutics both had 8 articles in the media. NewAmsterdam Pharma's average media sentiment score of 0.87 beat Summit Therapeutics' score of 0.39 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NewAmsterdam Pharma beats Summit Therapeutics on 9 of the 14 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

NewAmsterdam Pharma (NASDAQ:NAMS) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

NewAmsterdam Pharma presently has a consensus target price of $48.00, indicating a potential upside of 49.11%. Axsome Therapeutics has a consensus target price of $251.26, indicating a potential upside of 11.85%. Given NewAmsterdam Pharma's higher probable upside, equities research analysts clearly believe NewAmsterdam Pharma is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NewAmsterdam Pharma has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Axsome Therapeutics has a net margin of -26.59% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Axsome Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. Axsome Therapeutics is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.57M	166.77	-$203.82M	-$1.79	N/A
Axsome Therapeutics	$638.50M	18.10	-$183.17M	-$3.73	N/A

In the previous week, Axsome Therapeutics had 5 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 13 mentions for Axsome Therapeutics and 8 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.87 beat Axsome Therapeutics' score of 0.51 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NewAmsterdam Pharma and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAMS vs. The Competition

Export

Metric	NewAmsterdam Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.76B	$2.90B	$6.25B	$12.49B
Dividend Yield	N/A	1.79%	2.69%	5.30%
P/E Ratio	-17.98	17.64	21.07	24.34
Price / Sales	166.77	484.07	556.32	125.86
Price / Cash	N/A	56.38	42.31	57.88
Price / Book	5.39	3.84	9.78	6.76
Net Income	-$203.82M	$75.85M	$3.56B	$337.09M
7 Day Performance	-11.95%	-1.74%	-0.18%	1.50%
1 Month Performance	13.23%	22.80%	4.95%	6.18%
1 Year Performance	72.23%	21.59%	28.44%	35.62%

NewAmsterdam Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAMS NewAmsterdam Pharma	3.5026 of 5 stars	$32.19 +1.5%	$48.00 +49.1%	+67.5%	$3.76B	$22.57M	N/A	4	Positive News
GMAB Genmab A/S	4.0221 of 5 stars	$26.89 +0.1%	$39.07 +45.3%	+9.6%	$16.77B	$3.72B	20.37	3,029
ASND Ascendis Pharma A/S	4.6375 of 5 stars	$239.65 -3.0%	$295.39 +23.3%	+23.3%	$15.41B	$865.78M	27.64	1,189	Positive News Short Interest Decrease
BBIO BridgeBio Pharma	3.4898 of 5 stars	$67.73 -2.0%	$88.90 +31.3%	+80.1%	$13.27B	$502.08M	N/A	400	Analyst Forecast
SMMT Summit Therapeutics	2.1608 of 5 stars	$17.00 +2.3%	$26.05 +53.3%	-16.2%	$13.19B	N/A	N/A	110	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAMS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. GMAB, ASND, BBIO, SMMT, and AXSM

How does NewAmsterdam Pharma compare to Genmab A/S?

Summary

How does NewAmsterdam Pharma compare to Ascendis Pharma A/S?

Summary

How does NewAmsterdam Pharma compare to BridgeBio Pharma?

Summary

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Summary

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. GMAB, ASND, BBIO, SMMT, and AXSM

How does NewAmsterdam Pharma compare to Genmab A/S?

Do analysts rate NAMS or GMAB?

Does the media refer more to NAMS or GMAB?

Do insiders & institutionals have more ownership in NAMS or GMAB?

Which has stronger valuation and earnings, NAMS or GMAB?

Which has more risk & volatility, NAMS or GMAB?

Is NAMS or GMAB more profitable?

Summary

How does NewAmsterdam Pharma compare to Ascendis Pharma A/S?

Does the media prefer ASND or NAMS?

Do insiders and institutionals believe in ASND or NAMS?

Which has more risk & volatility, ASND or NAMS?

Do analysts prefer ASND or NAMS?

Is ASND or NAMS more profitable?

Which has preferable valuation & earnings, ASND or NAMS?

Summary

How does NewAmsterdam Pharma compare to BridgeBio Pharma?

Do insiders & institutionals believe in NAMS or BBIO?

Do analysts recommend NAMS or BBIO?

Is NAMS or BBIO more profitable?

Which has preferable earnings & valuation, NAMS or BBIO?

Which has more risk & volatility, NAMS or BBIO?

Does the media prefer NAMS or BBIO?

Summary

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Which has stronger valuation & earnings, SMMT or NAMS?

Do institutionals and insiders believe in SMMT or NAMS?

Is SMMT or NAMS more profitable?

Do analysts recommend SMMT or NAMS?

Which has more volatility & risk, SMMT or NAMS?

Does the media prefer SMMT or NAMS?

Summary

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

Do analysts rate NAMS or AXSM?

Do institutionals & insiders hold more shares of NAMS or AXSM?

Which has more volatility & risk, NAMS or AXSM?

Is NAMS or AXSM more profitable?

Which has stronger earnings & valuation, NAMS or AXSM?

Does the media prefer NAMS or AXSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools